Martin Samuel Bates's Form 4 filing
Celldex Therapeutics, Inc. (CLDX) · filed Jun 3, 2024
- Accession no.
- 0001415889-24-015147
- Filed
- Jun 3, 2024
- Trade date
- May 30, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.19M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Martin Samuel BatesCIK 0001709024 | Officer (SVP AND CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 30, 2024 | Common Stock | MOption exerciseAcquired | +25,000 | $10.38 | +$259,500 | 60,128 | Direct | |
| May 30, 2024 | Common Stock | SSaleDisposed | −35,000 | $34.05 | −$1,191,750 | 25,128 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 30, 2024 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 80,600 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.